VanEck Environmental Services ETF EVX
41.72 USD +0.89 (+2.17%)
At closeNov 4, 2026, 4:00 PM EST
41.72 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
41.09 Day range 41.72
36.55 52-week range 42.44
- YTD
- +9.13%
- 1 year
- +12.60%
News
globenewswire.com Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia Data will be presented in a poster session at the American Society of Hematology…
globenewswire.com Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio…
globenewswire.com Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 COPENHAGEN, Denmark, October 23, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform,…
globenewswire.com Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform,…
marketbeat.com These 3 ETFs Could Benefit From the Parts of Inflation That Won't Go Away It's not just the cost of goods that is rising, although inflation remains a persistent source of consumer frustration. The U.S. services sector saw growth cool in September, even as domestic demand…
globenewswire.com Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will…
globenewswire.com Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it…
globenewswire.com Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present…
globenewswire.com Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data…
globenewswire.com Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present new…
globenewswire.com Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new…
globenewswire.com Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the…
businesswire.com VanEck Announces Year-End Distributions for VanEck Equity ETFs NEW YORK--(BUSINESS WIRE)--VanEck announced today the 2025 annual distributions per share for its VanEck equity exchange-traded funds.
newsfilecorp.com European Electric Metals to Acquire Miminiska Gold Property in Ontario, Name Change to Canadian Goldfields Discovery Corp. and Appointment of John Booth as CEO Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - European Electric Metals Inc. (TSXV: EVX) (the "Company") is pleased to announce that it has entered into a mineral property…
accessnewswire.com Storm Exploration Enters Agreement to Sell the Miminiska Project VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / Storm Exploration Inc. (TSXV:STRM) ("Storm" or the "Company") is pleased to announce that it has entered into a mineral property purchase…
globenewswire.com Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 COPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data…
newsfilecorp.com European Electric Metals Announces Resumption of Trading Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - European Electric Metals Inc. (TSXV: EVX) (the "Company") announces that trading of the Company's common shares on the TSX Venture…
globenewswire.com Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 COPENHAGEN, Denmark, October 17, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new two-year…
globenewswire.com Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 COPENHAGEN, Denmark, October 13, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present a wide range…
benzinga.com Ecolab Navigates Soft Demand, Tariffs With Margin Gains, Confirms Full-Year Forecast Ecolab Inc. (NYSE:ECL) reported Q1 sales of $3.69 billion, down 2% Y/Y and missing consensus estimate of $3.70 billion. Organic sales grew 3% Y/Y.
benzinga.com Ecolab Q3 Earnings: Beats On EPS, Misses On Sales, Revises Annual EPS Forecast & More (CORRECTED) Ecolab reported lower Q3 sales growth of 1%, missing consensus estimate. Organic sales up 4%, operating income up 17%. Revised FY24 outlook.
benzinga.com Why Waste Management Shares Are Diving Today Waste Management reported worse-than-expected Q2 FY24 results, with sales of $5.402B and adjusted EPS of $1.82. Free cash flow increased 41.1%.
benzinga.com Waste Management To Acquire Stericycle For $62.00/Share In Cash, At 20% Premium Waste Management agreed to acquire Stericycle, adding medical waste & document shredding services. Both stocks have seen gains in past 12 months.
benzinga.com Waste Management Mulls $3B Sale Of RNG Business: Report Waste Management is seeking to sell its renewable natural gas business for about $3 billion. The company is working with JPMorgan to gauge interest from potential buyers.